SCL-1 - CAS 1061105-16-5

SCL-1 is an orally active anti-PD-1/PD-L1 inhibitor that disrupts the interaction between PD-1 and PD-L1. It enhances the numbers of T cells, B cells, and natural killer cells. SCL-1 exhibits potent tumor growth inhibitory effects by inducing effector T cells within the tumor and upregulating the expression of long non-coding RNAs as neoantigens, thereby activating cytotoxic T lymphocytes. SCL-1 is applicable in cancer research, including studies on triple-negative breast cancer.

PD-1/PD-L1

Cell Cycle/Checkpoint, Immunology/Inflammation, Apoptosis

1061084

C18H23F3N6O

396.41

O=C(N1CCCCC1C)C2CCN(C3=NN4C(=NN=C4C(F)(F)F)C=C3)CC2

-20°C

Ice Packs

Small Compound